Quantcast
Last updated on April 17, 2014 at 7:54 EDT

Latest Cardiac surgery Stories

2013-11-05 11:53:57

Loyola University Medical Center is the only Chicago hospital participating in a landmark clinical trial of an artificial aortic heart valve that does not require open heart surgery. First results from the trial were announced at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco. Results were positive, with high survival rates and low rates of stroke. “This is a major breakthrough,” said Fred Leya, MD, co-principal investigator at the Loyola...

2013-11-01 23:04:33

The global cardiovascular surgical devices market was valued at $29.7 billion in 2012 and is expected to reach nearly $31.7 billion in 2013. BCC Research projects the market to grow to nearly $47.2 billion by 2018, and register a five-year compound annual growth rate (CAGR) of 8.3% from 2013 to 2018. Wellesley, MA (PRWEB) November 01, 2013 According to a new technical market research report, Cardiovascular Surgical Devices: Technologies and Global Markets from BCC Research...

2013-11-01 11:28:50

'Hybrid procedure' combining minimally invasive corornary artery bypass surgery (CABG) with percutaneous coronary intervention is feasible and safe compared with traditional CABG A hybrid approach to treating coronary artery disease that involves a "hybrid procedure" combining a minimally invasive bypass surgery with percutaneous coronary intervention (PCI) was found to be feasible and safe in a clinical trial. This is the first randomized study of the technique. These findings were...

2013-10-31 20:21:52

New Data Announced At TCT 2013 Demonstrate Successful Deployment In All 120 Patients With No Severe Paravalvular Regurgitation At 30 Days San Francisco, Oct. 31, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX) Lotus(TM) Valve System met a key performance measure in the treatment of symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement, according to new data released today at the Transcatheter Cardiovascular...

2013-10-30 20:24:51

Results Show Treatment Provides Clinical Benefits and Improves Quality of Life for Patients with Debilitating Mitral Valve Disease Who Are at Prohibitive Surgical Risk ABBOTT PARK, Ill., Oct. 30, 2013 /PRNewswire/ -- Abbott today announced clinically meaningful changes to quality of life, a reduction in rehospitalization for heart failure, and functional improvements for patients treated with the company's first-in-class, catheter-based MitraClip(®) therapy for patients with degenerative...

2013-10-30 16:01:03

Persons with Alzheimer's disease suffer from ischaemic heart diseases more frequently than others, yet they undergo related procedures and surgery less frequently than persons with no diagnosed AD, according to a nation-wide register-based study carried out at the University of Eastern Finland. The study involved a total of 28,093 persons; that is every community-dwelling person with a diagnosed Alzheimer's disease living in Finland on 31 December 2005. According to the data obtained from...

2013-10-30 14:09:54

Clinical trial finds that COREVALVE reduces rate of death and stroke in sickest patients with aortic stenosis In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic stenosis at "extreme risk" for surgery. Results of the COREVALVE EXTREME RISK trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular...

2013-10-29 23:28:30

As the US population ages and obesity rises, cardiovascular device markets reach billions in market value. Vancouver, BC (PRWEB) October 29, 2013 iData Research, the leading global authority in medical device and pharmaceutical market research, has published a new report series for the U.S. Cardiology Device Markets. Cardiovascular disease is much more prevalent among patients over 55 years of age; therefore as the U.S. population ages, the incidence of cardiovascular disease will...

2013-10-29 08:31:53

--Preclinical Studies Show Innovative Transcatheter Product to Treat Mitral Regurgitation is Safe, Technically Feasible and Results in a Well-Functioning Mitral Bioprosthesis- --Sets Stage for First-in-Human Implantations Targeted for Early 2014-- TSX Venture Exchange: NVC VANCOUVER, Oct. 29, 2013 /PRNewswire/ - Neovasc Inc. (TSXV: NVC) today announced that a review of results from preclinical studies of its Tiara(TM)( )valve for the transcatheter treatment of mitral...

2013-10-28 12:25:36

NATICK, Mass., Oct. 28, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful innovation to clinicians and patients through a robust schedule of sponsored research presentations at the 25(th) Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, October 27 - November 2 in San Francisco. The clinical...


Latest Cardiac surgery Reference Libraries

0_886104d1c1c698f3a531e056704457d5
2010-10-14 16:46:25

The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...

More Articles (1 articles) »